| Literature DB >> 30171206 |
Yolanda Guillén1,2, Marc Noguera-Julian1,2,3, Javier Rivera1,3, Maria Casadellà1,2, Alexander S Zevin4, Muntsa Rocafort1,2, Mariona Parera1, Cristina Rodríguez1, Marçal Arumí1, Jorge Carrillo1,2, Beatriz Mothe1,3,5, Carla Estany5, Josep Coll1,5, Isabel Bravo5, Cristina Herrero5, Jorge Saz6, Guillem Sirera5, Ariadna Torrella7, Jordi Navarro2,7, Manuel Crespo8, Eugènia Negredo2,3,5, Christian Brander1,2,3,9, Julià Blanco1,2,3, Maria Luz Calle3, Nichole R Klatt4, Bonaventura Clotet1,2,3,5, Roger Paredes10,11,12,13.
Abstract
Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. Using a similar approach in 156 subjects with different HIV-1 phenotypes, we found a strong, independent, dose-effect association between nadir CD4+ T-cell counts and LGC. As in other diseases involving intestinal inflammation, the gut microbiomes of subjects with LGC were enriched in gram-negative Bacteroides, acetogenic bacteria and Proteobacteria, which are able to metabolize reactive oxygen and nitrogen species; and were depleted in oxygen-sensitive methanogenic archaea and sulfate-reducing bacteria. Interestingly, subjects with LGC also showed increased butyrate levels in direct fecal measurements, consistent with enrichment in Roseburia intestinalis despite reductions in other butyrate producers. The microbiomes of subjects with LGC were also enriched in bacterial virulence factors, as well as in genes associated with beta-lactam, lincosamide, tetracycline, and macrolide resistance. Thus, low nadir CD4+ T-cell counts, rather than HIV-1 serostatus per se, predict the presence of gut dysbiosis in HIV-1 infected subjects. Such dysbiosis does not display obvious HIV-specific features; instead, it shares many similarities with other diseases featuring gut inflammation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30171206 DOI: 10.1038/s41385-018-0083-7
Source DB: PubMed Journal: Mucosal Immunol ISSN: 1933-0219 Impact factor: 7.313